| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5605674 | TEVA BRANDED PHARM | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US8834849 | TEVA BRANDED PHARM | Medicinal aerosols and methods of delivery thereof |
Jun, 2017
(6 years ago) | |
| US7566445 | TEVA BRANDED PHARM | Medicinal aerosols and methods of delivery thereof |
Jun, 2017
(6 years ago) | |
| US6446627 | TEVA BRANDED PHARM | Inhaler dose counter |
Dec, 2017
(6 years ago) | |
| US7105152 | TEVA BRANDED PHARM | Suspension aerosol formulations |
Sep, 2023
(7 months ago) | |
| US8132712 | TEVA BRANDED PHARM | Metered-dose inhaler |
Sep, 2028
(4 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(7 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Proair Hfa is owned by Teva Branded Pharm.
Proair Hfa contains Albuterol Sulfate.
Proair Hfa has a total of 14 drug patents out of which 5 drug patents have expired.
Expired drug patents of Proair Hfa are:
- US5605674
- US8834849
- US7566445
- US6446627
- US7105152
Proair Hfa was authorised for market use on 29 October, 2004.
Proair Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Proair Hfa are possible to be released after 01 January, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 16, 2011 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
PROAIR HFA family patents
